Compare AMC ENTERTAINMENT HOLDINGS, INC. (AMC) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMC ENTERTAINMENT HOLDINGS, INC. vs Amphastar Pharmaceuticals Inc — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $1.88 (market cap $1.69B), while Amphastar Pharmaceuticals Inc trades at $19.3 (market cap $826.08M). The key difference: AMC ENTERTAINMENT HOLDINGS, INC. is far larger — about 2× Amphastar Pharmaceuticals Inc's market cap, and AMC ENTERTAINMENT HOLDINGS, INC. pays a 0.11% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMC | AMPH | |
|---|---|---|
Market Cap | $1.69B | $826.08M |
Sector | Media | Health |
52-Week High | $3.54 | $30.81 |
52-Week Low | $0.95 | $16.87 |
Enterprise Value | $9.28B | $1.22B |
Dividend Yield | 0.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMC trades at $1.89, down 0.53% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 EPS of -$0.36, missing expectations, while revenue trends show modest growth from $4.6B in 2024 to $4.85B in 2025. Recent news highlights box office recovery optimism and a $200 million stock offering that caused dilution concerns.
Outlook remains challenging with persistent net losses and high debt burden, though analyst consensus targets $1.90 with 32% buy ratings. Key risks include ongoing dilution from equity offerings, competitive pressures in entertainment, and the need for sustained box office recovery to improve cash flow and profitability.
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
